1st Quarter - Report

AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Firm
Client
Income
—
Expenses
$387,402
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

TRICARE rules affecting beneficiary access to clinical laboratory services.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: SENATE; Office of Management & Budget (OMB); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Defense, Dept of (DOD); White House Office; Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Medicare Payment Advisory Commission (MedPAC); SENATE; Congressional Budget Office (CBO); Government Accountability Office (GAO); White House Office; Centers For Medicare and Medicaid Services (CMS); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: H.R. 4302 (113th)

Medicare/Medicaid MMM

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); Defense, Dept of (DOD); Congressional Budget Office (CBO); SENATE; Medicare Payment Advisory Commission (MedPAC); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 4302 (113th)

Budget/Appropriations BUD

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law. TRICARE rules affecting beneficiary access to clinical laboratory services.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); SENATE; Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Office of Management & Budget (OMB); Defense, Dept of (DOD); White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Bills named: H.R. 4302 (113th)

Medical/Disease Research/Clinical Labs MED

Medicare Clinical Laboratory Fee Schedule and Physician Fee Schedule reimbursement and coverage issues, including H.R.4302, the Protecting Access to Medicare Act of 2014, pricing for molecular diagnostic tests, and other items in the Final FY2015 PFS Rule. Proposed FDA regulation of laboratory-developed tests. Closing the in-office ancillary services exception to the federal self-referral law.

LobbyistCovered position, as disclosed
JO ANNE GLISSON —
JULIE A KHANI —
SCOTT VAN BUREN MCGOOHAN —
ALAN MERTZ —
FRANCESCA FIERRO O'REILLY —
THOMAS B SPARKMAN —

Contacted: Food & Drug Administration (FDA); Office of Management & Budget (OMB); Medicare Payment Advisory Commission (MedPAC); Congressional Budget Office (CBO); White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); Government Accountability Office (GAO); Health & Human Services, Dept of (HHS)

Bills named: H.R. 4302 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.